Literature DB >> 10628805

Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom.

O S Pedersen1, E B Pedersen.   

Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are promising drugs for the treatment of HIV when used in combination with other anti-HIV drugs such as nucleoside reverse transcriptase (RT) inhibitors and protease inhibitors. The first generation of NNRTIs have, however, suffered from the rapid development of resistance. This review discusses the properties of the FDA-approved NNRTI drugs and focuses on the recent efforts being made to produce second generation inhibitors that circumvent this resistance problem.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628805     DOI: 10.1177/095632029901000601

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  19 in total

1.  3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.

Authors:  Elena Cichero; Laura Buffa; Paola Fossa
Journal:  J Mol Model       Date:  2010-10-05       Impact factor: 1.810

2.  Computational studies of the binding mode and 3D-QSAR analyses of symmetric formimidoester disulfides: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitor.

Authors:  Elena Cichero; Sara Cesarini; Andrea Spallarossa; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2008-12-09       Impact factor: 1.810

3.  Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses.

Authors:  Elena Cichero; Sara Cesarini; Andrea Spallarossa; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2009-01-20       Impact factor: 1.810

4.  Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.

Authors:  John M Muchiri; Dongge Li; Carrie Dykes; Robert A Bambara
Journal:  Biochemistry       Date:  2013-07-09       Impact factor: 3.162

5.  HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures.

Authors:  Anderson Coser Gaudio; Carlos Alberto Montanari
Journal:  J Comput Aided Mol Des       Date:  2002-04       Impact factor: 3.686

6.  Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues.

Authors:  Zhenshan Zhang; Mingyue Zheng; Li Du; Jianhua Shen; Xiaomin Luo; Weiliang Zhu; Hualiang Jiang
Journal:  J Comput Aided Mol Des       Date:  2006-08-08       Impact factor: 3.686

7.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; M Orlova; S G Sarafianos; E Arnold; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

8.  Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.

Authors:  Norikazu Sakakibara; Masanori Baba; Mika Okamoto; Masaaki Toyama; Yosuke Demizu; Takashi Misawa; Masaaki Kurihara; Kohji Irie; Yoshihisa Kato; Tokumi Maruyama
Journal:  Antivir Chem Chemother       Date:  2015-02

9.  Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Elena Cichero; Paola Fossa
Journal:  J Mol Model       Date:  2011-07-30       Impact factor: 1.810

10.  Docking mode of delvardine and its analogues into the p66 domain of HIV-1 reverse transcriptase: screening using molecular mechanics-generalized born/surface area and absorption, distribution, metabolism and excretion properties.

Authors:  Dipankar Sengupta; Deeptak Verma; Pradeep K Naik
Journal:  J Biosci       Date:  2007-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.